pharma news

News

Servier has signed the largest licensing deal in its history, paying $1.55bn upfront for Edgewise's muscular dystrophy business headed by sevasemten.

News

The SARCO41 study suggests Lilly's Verzenio could become the first targeted therapy for rare, aggressive tumour dedifferentiated liposarcoma.

News

The NHS digital single patient record (SPR) could result in 20,000 fewer A&E visits in England per year and save £20m a year, says the UK government.

News

Trials of AstraZeneca's anselamimab and Regeneron's Lynozyfic could deliver much-needed new therapeutic options for rare disease AL amyloidosis.

News

Millions of women with a breast cancer diagnosis could safely avoid chemotherapy that would not be effective, thanks to a genomics test.

News

Eli Lilly's relentless pipeline-building drive has continued with a licensing deal for Hanmi's sonefpeglutide, in phase 2 for short bowel syndrome.